SynthesisFrontiers in endocrinology2026
Molecular architecture of GLUT4 trafficking and exocytosis in adipocytes and skeletal muscle: A systematic review and integrated conceptual framework.
Synthesis in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: GLUT4 exocytosis links insulin signaling to cellular glucose disposal in adipocytes and skeletal muscle. Evidence for its molecular regulation is dispersed across experimental models, trafficking stages, and signaling pathways. We systematically mapped the molecular evidence underlying GLUT4 vesicle mobilization, tethering, docking, and membrane fusion and compared adipocyte and skeletal-muscle mechanisms. Methods: We searched PubMed (MEDLINE), Scopus, and Embase, supplemented by ProQuest Dissertations & Theses and preprint repositories. Primary experimental studies examining molecular regulators of GLUT4 exocytosis using in vitro and in vivo models were eligible. Two reviewers independently performed study selection, data extraction, and quality appraisal in accordance with PRISMA 2020. The protocol was prospectively registered in PROSPERO. Findings were synthesized narratively and mapped using the prespecified evidence-tier framework. Results: Of 15,835 identified records, 350 primary experimental studies met the eligibility criteria. The evidence map identified 206 distinct molecular entries in adipocyte studies and 109 in skeletal-muscle studies, representing the breadth of reported associations rather than uniformly validated regulators. Both tissues showed partially overlapping late trafficking machinery involving SNARE- and exocyst-related components. Adipocyte evidence most consistently supported AKT2 -TBC1D4 (AS160) -RAB10 signaling together with TC10- and RAC1-associated cortical modules. Skeletal-muscle pathways integrated insulin-responsive signaling with contraction-, AMPK-, and calcium-associated inputs involving TBC1D1/TBC1D4, RAC1, and RAB8A/RAB13. Direct imaging and perturbation experiments provided the strongest evidence for step-specific roles, but much of the evidence derived from differentiated cell lines and rodent models. Discussion: GLUT4 trafficking in both tissues follows a shared broad logic of signal-dependent vesicle release, cortical targeting, and membrane insertion, while individual regulatory nodes differ in their contribution and evidence base. These findings support signal-to-trafficking coupling as a relevant mechanistic layer of insulin resistance and identify pathways requiring validation in physiologically relevant human models before therapeutic translation. Systematic Review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251105528.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.